Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Gastric cancer is a heterogeneous disease with diverse histological and genomic subtypes,
making it difficult to demonstrate treatment efficacy in clinical trials. However, recent efforts …

Background Precision oncology medicines represent a paradigm shift compared to non-
precision oncology medicines in cancer therapy, in some situations delivering more clinical …

Introduction Most predictive biomarkers approved for clinical use measure single analytes
such as genetic alteration or protein overexpression. We developed and validated a novel …

BACKGROUND The development of precision medicine is essential for personalized
treatment and improved clinical outcome, whereas biomarkers are critical for the success of …

High-grade gliomas (HGG) are devastating diseases in children and adults. In the pediatric
population, diffuse midline gliomas (DMG) harboring H3K27 alterations are the most …

Background Treatment options for triple-negative breast cancer (TNBC) are limited and
patients face a poor prognosis. Here, we sought to identify drugs that target TNBC …

Combination therapy is well established as a key intervention strategy for cancer treatment,
with the potential to overcome monotherapy resistance and deliver a more durable efficacy …

Abstract Background Clinical trials in Alzheimer's disease (AD) had high failure rates for
several reasons, including the lack of biological endpoints. Fluid-based biomarkers may …